Opinion|Videos|April 4, 2025
Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
Panelists discuss how high-quality imaging is crucial for accurately staging prostate cancer, guiding treatment decisions, and optimizing patient outcomes. Superior resolution and sensitivity of PSMA PET tracers enhance lesion detection, influencing surgical, radiation, and systemic therapy choices. Differences in tracer properties impact specificity, affecting treatment planning. Advanced imaging reduces uncertainty, improving risk stratification and therapeutic precision.
Advertisement
Video content above is prompted by the following:
- Briefly discuss the importance of imaging quality in guiding treatment decisions for prostate cancer. How do these quality differences impact your clinical decision-making?
Advertisement
Related to this article
Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.
The ACS now recommends biennial PSA screening for average-risk men aged 50 to 69 years and annual screening from age 45 for Black men.
NCCN guidelines now list the ArteraAI Prostate Test for risk stratification in patients with biochemical recurrence after radical prostatectomy.
A dual bispecific regimen of pasritamig and JNJ-9401 reduced PSA by at least 50% in 73% of heavily pretreated patients with metastatic CRPC.
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
In a retrospective study, high AI-derived whole-body tumor volume on PSMA PET-CT was associated with a 3.20-fold higher risk of death in prostate cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
2
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
3
Managing Emergencies During Outpatient Bispecific Step-Up Dosing
4
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
5